BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 22450967)

  • 1. The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria.
    Skinner-Adams TS; Peatey CL; Anderson K; Trenholme KR; Krige D; Brown CL; Stack C; Nsangou DM; Mathews RT; Thivierge K; Dalton JP; Gardiner DL
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3244-9. PubMed ID: 22450967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials.
    Skinner-Adams TS; Stack CM; Trenholme KR; Brown CL; Grembecka J; Lowther J; Mucha A; Drag M; Kafarski P; McGowan S; Whisstock JC; Gardiner DL; Dalton JP
    Trends Biochem Sci; 2010 Jan; 35(1):53-61. PubMed ID: 19796954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemical target validation studies of aminopeptidase in malaria parasites using alpha-aminoalkylphosphonate and phosphonopeptide inhibitors.
    Cunningham E; Drag M; Kafarski P; Bell A
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3221-8. PubMed ID: 18458130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmodium falciparum M1-aminopeptidase: a promising target for the development of antimalarials.
    González-Bacerio J; Fando R; del Monte-Martínez A; Charli JL; Chávez Mde L
    Curr Drug Targets; 2014; 15(12):1144-65. PubMed ID: 25341419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and cellular characterisation of the Plasmodium falciparum M1 alanyl aminopeptidase (PfM1AAP) and M17 leucyl aminopeptidase (PfM17LAP).
    Mathew R; Wunderlich J; Thivierge K; Cwiklinski K; Dumont C; Tilley L; Rohrbach P; Dalton JP
    Sci Rep; 2021 Feb; 11(1):2854. PubMed ID: 33536500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity.
    Edgar RCS; Malcolm TR; Siddiqui G; Giannangelo C; Counihan NA; Challis M; Duffy S; Chowdhury M; Marfurt J; Dans M; Wirjanata G; Noviyanti R; Daware K; Suraweera CD; Price RN; Wittlin S; Avery VM; Drinkwater N; Charman SA; Creek DJ; de Koning-Ward TF; Scammells PJ; McGowan S
    mBio; 2024 Jun; 15(6):e0096624. PubMed ID: 38717141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions.
    Drinkwater N; Vinh NB; Mistry SN; Bamert RS; Ruggeri C; Holleran JP; Loganathan S; Paiardini A; Charman SA; Powell AK; Avery VM; McGowan S; Scammells PJ
    Eur J Med Chem; 2016 Mar; 110():43-64. PubMed ID: 26807544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and chemical validation of
    Edgar RCS; Siddiqui G; Hjerrild K; Malcolm TR; Vinh NB; Webb CT; Holmes C; MacRaild CA; Chernih HC; Suen WW; Counihan NA; Creek DJ; Scammells PJ; McGowan S; de Koning-Ward TF
    Elife; 2022 Sep; 11():. PubMed ID: 36097817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminopeptidases of malaria parasites: new targets for chemotherapy.
    Trenholme KR; Brown CL; Skinner-Adams TS; Stack C; Lowther J; To J; Robinson MW; Donnelly SM; Dalton JP; Gardiner DL
    Infect Disord Drug Targets; 2010 Jun; 10(3):217-25. PubMed ID: 20334618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases.
    McGowan S; Oellig CA; Birru WA; Caradoc-Davies TT; Stack CM; Lowther J; Skinner-Adams T; Mucha A; Kafarski P; Grembecka J; Trenholme KR; Buckle AM; Gardiner DL; Dalton JP; Whisstock JC
    Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2449-54. PubMed ID: 20133789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bestatin-based chemical biology strategy reveals distinct roles for malaria M1- and M17-family aminopeptidases.
    Harbut MB; Velmourougane G; Dalal S; Reiss G; Whisstock JC; Onder O; Brisson D; McGowan S; Klemba M; Greenbaum DC
    Proc Natl Acad Sci U S A; 2011 Aug; 108(34):E526-34. PubMed ID: 21844374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibition of PfA-M1, over PfA-M17, by an amino-benzosuberone derivative blocks malaria parasites development in vitro and in vivo.
    Bounaadja L; Schmitt M; Albrecht S; Mouray E; Tarnus C; Florent I
    Malar J; 2017 Sep; 16(1):382. PubMed ID: 28934959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The M18 aspartyl aminopeptidase of the human malaria parasite Plasmodium falciparum.
    Teuscher F; Lowther J; Skinner-Adams TS; Spielmann T; Dixon MW; Stack CM; Donnelly S; Mucha A; Kafarski P; Vassiliou S; Gardiner DL; Dalton JP; Trenholme KR
    J Biol Chem; 2007 Oct; 282(42):30817-26. PubMed ID: 17720817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmodium falciparum: new molecular targets with potential for antimalarial drug development.
    Gardiner DL; Skinner-Adams TS; Brown CL; Andrews KT; Stack CM; McCarthy JS; Dalton JP; Trenholme KR
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1087-98. PubMed ID: 19883329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Potent and Selective Inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PfM18AAP) of Human Malaria via High-Throughput Screening.
    Spicer T; Fernandez-Vega V; Chase P; Scampavia L; To J; Dalton JP; Da Silva FL; Skinner-Adams TS; Gardiner DL; Trenholme KR; Brown CL; Ghosh P; Porubsky P; Wang JL; Whipple DA; Schoenen FJ; Hodder P
    J Biomol Screen; 2014 Aug; 19(7):1107-15. PubMed ID: 24619116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the Pathway and Dynamics of Bestatin Inhibition of the Plasmodium falciparum M1 Aminopeptidase PfA-M1.
    Yang W; Riley BT; Lei X; Porebski BT; Kass I; Buckle AM; McGowan S
    ChemMedChem; 2018 Dec; 13(23):2504-2513. PubMed ID: 30318749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents.
    Flipo M; Beghyn T; Leroux V; Florent I; Deprez BP; Deprez-Poulain RF
    J Med Chem; 2007 Mar; 50(6):1322-34. PubMed ID: 17326615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and antimalarial activity of novel, quinoline-based, zinc metallo-aminopeptidase inhibitors.
    Flipo M; Florent I; Grellier P; Sergheraert C; Deprez-Poulain R
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2659-62. PubMed ID: 12873488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingerprinting the substrate specificity of M1 and M17 aminopeptidases of human malaria, Plasmodium falciparum.
    Poreba M; McGowan S; Skinner-Adams TS; Trenholme KR; Gardiner DL; Whisstock JC; To J; Salvesen GS; Dalton JP; Drag M
    PLoS One; 2012; 7(2):e31938. PubMed ID: 22359643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The M17 leucine aminopeptidase of the malaria parasite Plasmodium falciparum: importance of active site metal ions in the binding of substrates and inhibitors.
    Maric S; Donnelly SM; Robinson MW; Skinner-Adams T; Trenholme KR; Gardiner DL; Dalton JP; Stack CM; Lowther J
    Biochemistry; 2009 Jun; 48(23):5435-9. PubMed ID: 19408962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.